High‐dose dual therapy and CYP2C19 polymorphism in Helicobacter pylori eradication

Abstract

Helicobacter pylori infect about 50% of the world's population. The efficacy of treatment using standard regimens has declined in recent years, mainly due to widespread development of antibiotic resistance. Use of enhanced acid suppression and antibiotics with lower risk to resistance, will shape the future of treatment for H pylori. High‐dose dual therapy (HDDT) can overcome the effect of CYP2C19 polymorphism thus enhancing acid suppression and may become an option in H pylori eradication.